Flint Animal Cancer Center

Safety and Effectiveness of GEM-IB/Docetaxel in Dogs with Osteosarcoma

Patient Disease:

Canine Osteosarcoma

Study Name:

Safety and Effectiveness of GEM-IB/Docetaxel in Dogs with Osteosarcoma

Purpose of the study:

  • The new drug GEM-IB combines a bone-targeting drug (ibandronate) with a potent cancer drug (gemcitabine) to increase the concentration of cancer drug exactly at the site of the tumor, and we are evaluating the use of this drug in combination with another chemotherapy agent (docetaxel)

  • To evaluate the safety and antitumor/anti-pain effects of this combined treatment given to dogs with osteosarcoma that have not yet been treated with surgery, radiation therapy or chemotherapy

Primary Eligibility Criteria:

  • Cytology-confirmed diagnosis of osteosarcoma of the leg with lameness present

  • Adequate blood work

  • No prior treatment with chemotherapy, radiation therapy, or bisphosphonates

Study Protocol:

  • Study drug combination given once every 21 days

  • Dogs will be rechecked 1, 3-4, 7, 14 and 21 days after the first treatment, then every three weeks thereafter

  • PET/CT performed to assess tumor response pre-treatment and at 7 and 21 days after the 1st treatment

Owner Responsibilities:

  • You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist

  • You are expected to make and keep all appointments associated with the study

Financial Incentives:

  • All costs associated with the study, including treatment of any side effects associated with the study treatments, will be covered by the study

  • Following your dog’s completion of the clinical trial, you will receive a credit of $1000 for continued treatment of your dog at the VTH